- Previous Close
91.78 - Open
91.82 - Bid 91.08 x --
- Ask 94.84 x --
- Day's Range
91.74 - 95.68 - 52 Week Range
76.24 - 112.10 - Volume
15,058 - Avg. Volume
11,052 - Market Cap (intraday)
5.162B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
29.61 - EPS (TTM)
3.14 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield 1.10 (1.33%)
- Ex-Dividend Date May 22, 2023
- 1y Target Est
--
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
diasoringroup.com/en3,278
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 0GZX.IL
View MorePerformance Overview: 0GZX.IL
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is FTSE MIB Index (FTSEMIB.MI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0GZX.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0GZX.IL
View MoreValuation Measures
Market Cap
4.94B
Enterprise Value
5.76B
Trailing P/E
26.17
Forward P/E
19.84
PEG Ratio (5yr expected)
1.30
Price/Sales (ttm)
4.17
Price/Book (mrq)
2.75
Enterprise Value/Revenue
4.86
Enterprise Value/EBITDA
21.80
Financial Highlights
Profitability and Income Statement
Profit Margin
14.98%
Return on Assets (ttm)
5.64%
Return on Equity (ttm)
12.24%
Revenue (ttm)
1.25B
Net Income Avi to Common (ttm)
187.51M
Diluted EPS (ttm)
3.14
Balance Sheet and Cash Flow
Total Cash (mrq)
256.29M
Total Debt/Equity (mrq)
80.09%
Levered Free Cash Flow (ttm)
179.61M